Madrigal expands board to nine, appoints J&J R&D chief John C. Reed

MADRIGAL PHARMACEUTICALS, INC.

Board grew from 8 to 9 members; Reed elected Class II director, term to 2027 annual meeting.
Reed is EVP Innovative Medicine R&D at Johnson & Johnson, leading oncology, immunology, neuroscience research.
Compensation: $50k cash retainer, $10k for Science & Tech Committee, $675k equity grant (50% options, 50% RSUs).
Reed joins Science and Technology Committee; no material transactions disclosed under Item 404(a).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John C. Reed

Director

MDGL · MADRIGAL PHARMACEUTICALS, INC.

Effective: 2026-08-11
Filed: August 12, 2026, 8:18 AM ET

On August 11, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John C. Reed was elected as Director at MADRIGAL PHARMACEUTICALS, INC..

Action: elected
Role: Director

Exact text from the filing

On August 11, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026.

View on SEC.gov

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-055962

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.